Enhanced anti-tumor efficacy of Electrochemotherapy combined with marginal surgery in dogs with Mast Cell Tumors and Soft Tissue Sarcomas
This large retrospective study of 605 dogs in the United States demonstrates that electrochemotherapy combined with marginal surgery significantly decreases local recurrence and extends progression-free survival for mast cell tumors and soft tissue sarcomas, particularly when tailored to tumor grade.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
In the world of veterinary medicine, two types of cancerous growths are particularly common on dogs: mast cell tumors and soft tissue sarcomas. These are not merely lumps under the skin; they are complex diseases that behave differently depending on their grade, or how aggressive they appear under a microscope. The standard approach to treating these tumors has long been surgery, with the goal of cutting the growth out completely. However, the anatomy of a dog's body often makes this difficult. On a paw, a face, or a leg, there is simply not enough loose skin to cut wide margins around a tumor without causing significant damage or leaving the animal unable to walk or see properly. When surgeons cannot remove the entire tumor with a clean border, the risk of the cancer returning in that same spot is high. For decades, the options for preventing this return were limited, often involving radiation therapy, which requires specialized equipment not available in every clinic, or chemotherapy, which affects the entire body.
Researchers have been exploring a different path that combines surgery with a technique called electrochemotherapy. This method involves using electricity to temporarily open tiny pores in the cells of a tumor, allowing cancer-fighting drugs to enter much more effectively than they would on their own. The question facing veterinarians was whether this combination could serve as a reliable safety net for dogs who had undergone surgery that left some cancer cells behind. A new study from a veterinary referral center in the United States set out to answer this by looking at a large group of dogs treated with this specific approach. The goal was to see if adding this electrical treatment after surgery could stop the cancer from growing back, offering a local solution that avoids the heavy side effects of systemic drugs.
The study examined the medical records of 605 dogs treated between 2020 and 2024. All these animals had undergone surgery for either mast cell tumors or soft tissue sarcomas, but in every case, the surgeons determined that the edges of the removed tissue were not completely clear of cancer cells. Instead of immediately turning to radiation or aggressive chemotherapy, these dogs received a follow-up treatment called electrochemotherapy. The process began with the administration of a drug called bleomycin through an intravenous line. Four minutes later, a second drug, cisplatin, was injected directly into the scar left by the surgery. Once the drugs were in place, the area was treated with a specialized device that delivered short, controlled pulses of electricity. This electrical shock did not burn the tissue; rather, it created microscopic openings in the cell membranes, allowing the chemotherapy drugs to flood inside the remaining cancer cells and destroy them.
The results of this large-scale review were encouraging. The researchers found that this combination of surgery and electrochemotherapy was highly effective at preventing the cancer from returning to the surgical site. For the dogs with the least aggressive forms of mast cell tumors, the average time before any sign of the cancer returned was nearly five years. Even for dogs with more aggressive, high-grade tumors, the treatment provided a significant period of control, with many dogs remaining free of local recurrence for years. Specifically, dogs with high-grade soft tissue sarcomas saw a median of about 14 months without the cancer returning to the scar, a substantial improvement over the typical timeline for incomplete surgeries. The study noted that the treatment worked well regardless of whether the tumor was on the surface of the skin or buried deeper underneath, suggesting that the electrical pulses could reach deep enough to treat the hidden cells effectively.
Safety was a major focus of the evaluation, and the treatment proved to be remarkably gentle. The most common side effect observed was a temporary muscle twitching during the electrical pulses, which is a normal reaction to the shock and stops immediately when the pulse ends. In some cases, the treated area developed a small amount of dead tissue, or necrosis, which is a sign that the cancer cells were dying off. This occurred in about one-fifth of the cases and typically healed on its own within a month. Crucially, the dogs did not suffer from the severe systemic side effects often associated with traditional chemotherapy, such as vomiting or a weakened immune system, because the drugs were targeted directly to the scar and activated by the electricity.
This research represents a significant step forward for veterinary oncology, particularly for clinics that do not have access to radiation therapy machines. It suggests that for dogs with difficult-to-reach tumors where clean surgical margins are impossible, electrochemotherapy offers a powerful alternative. The study indicates that this method can provide long-term local control, giving dogs and their owners more time without the burden of heavy systemic toxicity. While the researchers noted that dogs with very aggressive tumors still required additional systemic treatments to manage the risk of cancer spreading elsewhere in the body, the local control achieved at the surgical site was a clear success. The findings support the continued use of this therapy as a standard option for managing these common and challenging canine cancers.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.